prmaconsulting®

pricing, reimbursement
& market access

Mapping orphan drug policies and pathways across 12 markets

SUMMARY

Comprehensive mapping of the policy landscape and access pathways provided insights into the opportunities and challenges for assets and content for global value dossiers.

CLIENT SITUATION

A leading biopharmaceutical client with a pipeline of drugs in development for rare diseases wanted to comprehensively map the pricing and reimbursement (P&R) policy environment and understand potential market access pathways for orphan drugs in 12 countries globally.

PRMA CONSULTING SOLUTION

Secondary research

We reviewed published articles, the gray literature, and the websites of key agencies to understand the health technology assessment (HTA) and P&R of orphan drugs in the scope countries, including the policy landscape, access and funding pathways, and payer evidence requirements.

In addition, we reviewed HTAs of specific orphan drugs; these case studies provided further insights into the evaluation process in each country and the implications for orphan drugs.

Primary research

Semi-structured interviews were conducted with one or two payers in each scope country to validate findings and answer any remaining questions on the current and emerging policy landscape and HTA and P&R of orphan drugs that arose during secondary research.

CLIENT VALUE

- The current and emerging policy landscape and access pathways for orphan drugs were comprehensively mapped.
- Insights into the opportunities and challenges for orphan drugs in the client's pipeline were highlighted.
- The final report provided content that could be included in global value dossiers as environmental context.

Figure 6 HTA/P&R of orphan drugs in Germany



2116

+44 (0)1252 786284
info@prmaconsulting.com